Association between isotretinoin (Roaccutanne) use and changes in periodontal clinical parameters and MMP-8 and MMP-9 salivary levels.

Reham Al Jasser ,Manal Alkenani ,Sadeem Alqahtani ,Razaan S Alaqeely ,Afnan Alzahrani ,Mohammed Al-Haddab ,Ibrahim A Al-Hoqail ,Saleh Aloraini

doi:10.52586/4933

Reham Al Jasser , Manal Alkenani + Show 6 more

Open Access

https://doi.org/10.52586/4933

Copy DOI

Abstract

Aims: to evaluate changes in clinical periodontal parameters, salivary levels of MMP-8 and MMP-9, in individuals taking Isotretinoin (INN), and compare with individuals not taking the medication and to compare findings among different stages of periodontal disease and healthy periodontium. Material and methods: A case-control study was conducted with a total of 180 human adults divided into six groups. Clinical parameters, including pocket depth (PD), clinical attachment level (CAL), and bleeding on probing (BOP) were measured at six sites per tooth. Whole unstimulated saliva samples were collected from all subjects to detect salivary level of MMP-8, MMP-9 using Enzyme-linked immunosorbent assay (ELISA). Data were analyzed using IBM SPSS Software. Kruskal Wallis test and Mann-Whitney U-tests were used to test any significant differences in any of the groups on all parameters. Pearson Chi-square test was used to compare the distribution of categorical responses across the study groups. All tests were compared at a significance level of 0.05. Results: In Gingivitis cases, INN group was found to have significantly less BOP (P < 0.0001). In Periodontitis cases, INN group showed significant difference in BOP (P < 0.0001). MMP-8 and MMP-9 were significantly lower among Periodontitis cases taking INN compared to the same group not taking the medication (P < 0.0001). Conclusion: INN assists in reducing clinical and biological signs of inflammation related to periodontal disease progression. INN may be a future additive medication to be further evaluated for treating periodontal disease.

Highlights

Isotretinoin (INN); which is known as 13-cisRetinoic acid, is an oral administrative drug that belongs to a class of drugs known as retinoids [1]
The objective of this study was to evaluate changes in: (1) clinical periodontal parameters including: pocket depth (PD), clinical attachment level (CAL), bleeding on probing (BOP); and (2) salivary levels of MMP-8, matrix metalloproteinase-9 (MMP9) during treatment with oral INN in patients receiving the drug for a minimum of 3 months for cutaneous acne, and to compare these findings among patients with different stages of periodontal disease and healthy periodontium
This study illustrates the relationship between clinical periodontal parameters including: (PD), (CAL), and (BOP); as well as biological periodontal parameters which includes the salivary levels MMP-8 and Matrix Metalloproteinase9 (MMP-9) in relation to the use of INN

Summary

Introduction

Isotretinoin (INN); which is known as 13-cisRetinoic acid (brand name; Roaccutanne/Accutane-Roche, Switzerland), is an oral administrative drug that belongs to a class of drugs known as retinoids [1]. It is mostly used to treat severe nodular acne that has not responded to other treatment [2]. In terms of mechanism of action; INN is the only therapy that targets all major etiological factors implicated in acne [4]. This is achieved by influencing cell-cycle progression, cellular differentiation, cell survival, and apoptosis. It results in a significant reduction in sebum production from sebaceous glands, influences comedogenesis, lowers surface and ductal Propionibacterium acnes, and has antiinflammatory properties [5,6,7,8,9]

Objectives

Results

Conclusion